Prisma Health Fellowship in Urologic Oncology

Fellow volume. 100-130 cystectomies, 40% continent. greater than 300 robot and 300 complex open

[High-Yield Urology @HighYieldUro]

🚨T-minus 3️⃣ months to go until the @AmerUrological In-Service and @UroOnc OKAT exams ➡️ great time to get ahold of @HighYieldUro 2026 📖🚀 https://t.co/b7EVZjnzDY

[Prisma Health Fellowship in Urologic Oncology @prisma_uroonc]

@daviesbj Plaque is protected. Patina.

[Shankar Siva @_ShankarSiva]

💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo:
🔹 RT (n=77) vs Obs (n=76)
🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006)
🔹OS trend ↑RT (68% vs 57%), not sig
🔹No ↑ severe late adverse events
👉Adjuvant RT ↑ control & DFS, esp T3/4 & N+ pts. #ASTRO25 #RadOnc

[Sia Daneshmand, M.D. @siadaneshmand]

Just published online in @JCO_ASCO : #SunRISe1 Phase IIb results show TAR-200 (novel intravesical drug releasing system) achieves 82.4% CR in BCG-unresponsive high-risk NMIBC—with durable responses (median DOR 25.8 mo) & low toxicity. A game-changer for pts with #NMIBC. @A@AndreaNecchi @USC_Urology @IBCG_BladderCA @BladderCaJrnl @JoeJacobMD1 @DrFelixGuerrero @griffoncanisius @dzainfeld @evanguelosx @KSMurrayUro @Sweiti @DocBladder @UroDocAsh @BladderCancerUS 🔗 https://t.co/OhkdZQRr8u

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

FDA approves UGN-102, mitomycin intravesical solution (ZUSDURI™ ) for Recurrent Low-Grade IR NMIBC

https://t.co/GbjGQhgu68 @UroGenPharma @UrogerliMD @siadaneshmand @MaxKates @IBCG_BladderCA @joanfundi

[Gabriel Fiscus @GabeFiscus]

Just completed the first FANS ureteroscopy at @PH_Surgery using the @DornierMedTech Hoover suction access sheath. A true game changer for the management of kidney stones!

[Bladder Cancer Advocacy Network @BladderCancerUS]

Bladder cancer care is evolving fast! From NMIBC to mUC, learn more with Drs. Sia Daneshmand (@siadaneshmand), Laura Bukavina (@laurabukavinamd), Matthew D. Galsky (@MattGalsky), & Sarah P. Psutka, MD, MS, FACS (@spsutkaMD)! https://t.co/WhovTmtHaB @PeerView

[Vignesh Packiam, MD @VigneshPackiam]

We need to be thoughtful about what our patients want and counsel them well so they make the best decision possible!!

Especially in the era of ever improvements in bladder sparing efficacy…. This data is super valuable

[UroToday.com @urotoday]

#Crossfire: Controversies in #Urology: double intravesical chemotherapy is preferred over new FDA-approved agents for BCG unresponsive #NMIBC: the price of success. #AUA25 written coverage by @chavarriagaj @UofT > https://t.co/9q7uYJnISI @Tullika_Garg @ctleeuro @VigneshPackiam @AmerUrological

[Vignesh Packiam, MD @VigneshPackiam]

LVI is tough. With our improved management and therapies I am generally aggressive in promoting bladder sparing for NMIBC - but this gives pause: T1 with LVI had higher node positivity rates than MIBC without LVI, at least in NCDB 2004-2014..

Need large granular series that include more variables (blue light, presence of LVI at re-TURBT) and contemporary agents (especially immune) to get more answers

https://t.co/bfOOS74gih

[European Urology @EUplatinum]

Editor's Choice: Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial by Agne Krilaviciute et al

Read the full article here: https://t.co/onQxNk0peU

Come back later to read the Editorial!

#UroSoMe #MedTwitter #eururol #editorschoice #highlightarticle #ProstateCancer #PCa #Spotlight

@GGiannarini

[UroToday.com @urotoday]

🚨 Promising alternative to BCG for #NMIBC! Drs. @SHPatelMD1 & @MaxKates @brady_urology sit down with @UroCancerMD @VUMCurology to discuss phase II trial results: 100% complete response at 3 months & 92% at 12 months with gemcitabine + docetaxel. Key takeaways: combination therapy logistics, maintenance strategies, & BCG shortage solutions. #WatchNow > https://t.co/tzbqxd2zp0 @urogabe

[Toni Choueiri, MD @DrChoueiri]

END OF YEAR TOP ALL CANCER TRIALS in 2024!

JUST in on 1 JAN 2025:

Paper 1:

#neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @A@ASCO @ProfCUBlankNKI

https://t.co/3ndFElEAA8

[Gabriel Fiscus @GabeFiscus]

@prisma_uroonc fellow Nick Noble giving an update on high impact bladder cancer articles of 2024. @UroOnc @RyanWerntzMD

[Tom Powles @tompowles1]

Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Robot-assisted Radical Cystectomy with IUD Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomized Controlled Trial
Confirms: similar outcomes, shorter OR time with ORC, lower EBL with RARC

https://t.co/xG4oDQFrGE
#BladderCancer

[Toni Choueiri, MD @DrChoueiri]

2/After 50 years of adjuvant trials on RCC (3 slides); #KEYNOTE564 demonstrates overall survival (OS) benefit!

[Tom Powles @tompowles1]

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo &amp; CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

[Prisma Health Fellowship in Urologic Oncology @prisma_uroonc]

@Agarwal_CaB @UroDocAsh @joanfundi What’s interesting is we have started to experiment with ctcs with comp like signatera. example of this is we had pt with nac. Post nac signatera elevated. Then rc with lnd. N1. Post rc signatera 0. Unclear what this means,prospective follow up correlating recurrence needed